Underinsurance  ||| S:0 E:15 ||| NNP
and  ||| S:15 E:19 ||| CC
adolescent  ||| S:19 E:30 ||| JJ
immunization  ||| S:30 E:43 ||| JJ
delivery  ||| S:43 E:52 ||| NN
in  ||| S:52 E:55 ||| IN
the  ||| S:55 E:59 ||| DT
United  ||| S:59 E:66 ||| NNP
States  ||| S:66 E:73 ||| NNPS
The  ||| S:73 E:77 ||| DT
goal  ||| S:77 E:82 ||| NN
was  ||| S:82 E:86 ||| VBD
to  ||| S:86 E:89 ||| TO
explore  ||| S:89 E:97 ||| VB
the  ||| S:97 E:101 ||| DT
association  ||| S:101 E:113 ||| NN
of  ||| S:113 E:116 ||| IN
being  ||| S:116 E:122 ||| VBG
underinsured  ||| S:122 E:135 ||| NNS
and  ||| S:135 E:139 ||| CC
receiving  ||| S:139 E:149 ||| VBG
doses  ||| S:149 E:155 ||| NNS
at  ||| S:155 E:158 ||| IN
a  ||| S:158 E:160 ||| DT
health  ||| S:160 E:167 ||| NN
department  ||| S:167 E:178 ||| NN
clinic  ||| S:178 E:185 ||| NN
( ||| S:185 E:186 ||| -LRB-
HDC ||| S:186 E:189 ||| NNP
)  ||| S:189 E:191 ||| -RRB-
with  ||| S:191 E:196 ||| IN
not  ||| S:196 E:200 ||| RB
receiving  ||| S:200 E:210 ||| VBG
all  ||| S:210 E:214 ||| DT
recommended  ||| S:214 E:226 ||| JJ
adolescent  ||| S:226 E:237 ||| JJ
vaccine  ||| S:237 E:245 ||| NN
doses ||| S:245 E:250 ||| NNS
.  ||| S:250 E:252 ||| .
A  ||| S:252 E:254 ||| DT
total  ||| S:254 E:260 ||| NN
of  ||| S:260 E:263 ||| IN
5657  ||| S:263 E:268 ||| CD
adolescents ||| S:268 E:279 ||| NNS
,  ||| S:279 E:281 ||| ,
13  ||| S:281 E:284 ||| CD
to  ||| S:284 E:287 ||| TO
17  ||| S:287 E:290 ||| CD
years  ||| S:290 E:296 ||| NNS
of  ||| S:296 E:299 ||| IN
age ||| S:299 E:302 ||| NN
,  ||| S:302 E:304 ||| ,
were  ||| S:304 E:309 ||| VBD
sampled  ||| S:309 E:317 ||| VBN
in  ||| S:317 E:320 ||| IN
the  ||| S:320 E:324 ||| DT
National  ||| S:324 E:333 ||| NNP
Immunization  ||| S:333 E:346 ||| NNP
Survey-Teen  ||| S:346 E:358 ||| NNP
in  ||| S:358 E:361 ||| IN
2006-2007 ||| S:361 E:370 ||| CD
.  ||| S:370 E:372 ||| .
A  ||| S:372 E:374 ||| DT
total  ||| S:374 E:380 ||| NN
of  ||| S:380 E:383 ||| IN
63.9 ||| S:383 E:387 ||| CD
%  ||| S:387 E:389 ||| NN
of  ||| S:389 E:392 ||| IN
all  ||| S:392 E:396 ||| DT
adolescents  ||| S:396 E:408 ||| NN
were  ||| S:408 E:413 ||| VBD
covered  ||| S:413 E:421 ||| VBN
by  ||| S:421 E:424 ||| IN
private  ||| S:424 E:432 ||| JJ
health  ||| S:432 E:439 ||| NN
insurance ||| S:439 E:448 ||| NN
.  ||| S:448 E:450 ||| .
Among  ||| S:450 E:456 ||| IN
privately  ||| S:456 E:466 ||| RB
insured  ||| S:466 E:474 ||| JJ
adolescents ||| S:474 E:485 ||| NNS
,  ||| S:485 E:487 ||| ,
approximately  ||| S:487 E:501 ||| RB
31.3 ||| S:501 E:505 ||| CD
%  ||| S:505 E:507 ||| NN
were  ||| S:507 E:512 ||| VBD
underinsured ||| S:512 E:524 ||| VBN
.  ||| S:524 E:526 ||| .
Compared  ||| S:526 E:535 ||| VBN
with  ||| S:535 E:540 ||| IN
fully  ||| S:540 E:546 ||| RB
insured  ||| S:546 E:554 ||| JJ
adolescents ||| S:554 E:565 ||| NNS
,  ||| S:565 E:567 ||| ,
underinsured  ||| S:567 E:580 ||| JJ
adolescents  ||| S:580 E:592 ||| NNS
were  ||| S:592 E:597 ||| VBD
more  ||| S:597 E:602 ||| RBR
likely  ||| S:602 E:609 ||| JJ
to  ||| S:609 E:612 ||| TO
receive  ||| S:612 E:620 ||| VB
doses  ||| S:620 E:626 ||| NNS
at  ||| S:626 E:629 ||| IN
an  ||| S:629 E:632 ||| DT
HDC  ||| S:632 E:636 ||| NNP
for  ||| S:636 E:640 ||| IN
tetanus-diphtheria  ||| S:640 E:659 ||| FW
toxoids ||| S:659 E:666 ||| FW
/ ||| S:666 E:667 ||| FW
tetanus  ||| S:667 E:675 ||| FW
toxoids-reduced  ||| S:675 E:691 ||| FW
diphtheria  ||| S:691 E:702 ||| FW
toxoids-acellular  ||| S:702 E:720 ||| FW
pertussis  ||| S:720 E:730 ||| FW
vaccine  ||| S:730 E:738 ||| FW
( ||| S:738 E:739 ||| -LRB-
25.1 ||| S:739 E:743 ||| NNP
%  ||| S:743 E:745 ||| NN
vs  ||| S:745 E:748 ||| VBD
6.2 ||| S:748 E:751 ||| CD
% ||| S:751 E:752 ||| NN
;  ||| S:752 E:754 ||| :
P  ||| S:754 E:756 ||| NNP
< ||| S:756 E:758 ||| SYM
.05 ||| S:758 E:761 ||| NNP
) ||| S:761 E:762 ||| -RRB-
,  ||| S:762 E:764 ||| ,
tetravalent  ||| S:764 E:776 ||| FW
meningococcal  ||| S:776 E:790 ||| FW
conjugate  ||| S:790 E:800 ||| FW
vaccine  ||| S:800 E:808 ||| FW
( ||| S:808 E:809 ||| -LRB-
11.5 ||| S:809 E:813 ||| CD
%  ||| S:813 E:815 ||| NN
vs  ||| S:815 E:818 ||| VBD
2.5 ||| S:818 E:821 ||| CD
% ||| S:821 E:822 ||| NN
;  ||| S:822 E:824 ||| :
P  ||| S:824 E:826 ||| NNP
< ||| S:826 E:828 ||| SYM
.05 ||| S:828 E:831 ||| NNP
) ||| S:831 E:832 ||| -RRB-
,  ||| S:832 E:834 ||| ,
and  ||| S:834 E:838 ||| CC
quadrivalent  ||| S:838 E:851 ||| JJ
human  ||| S:851 E:857 ||| JJ
papillomavirus  ||| S:857 E:872 ||| JJ
vaccine  ||| S:872 E:880 ||| NN
( ||| S:880 E:881 ||| -LRB-
16.2 ||| S:881 E:885 ||| CD
%  ||| S:885 E:887 ||| NN
vs  ||| S:887 E:890 ||| VBD
3.4 ||| S:890 E:893 ||| CD
% ||| S:893 E:894 ||| NN
;  ||| S:894 E:896 ||| :
P  ||| S:896 E:898 ||| NNP
< ||| S:898 E:900 ||| SYM
.05 ||| S:900 E:903 ||| NNP
) ||| S:903 E:904 ||| -RRB-
.  ||| S:904 E:906 ||| .
Also ||| S:906 E:910 ||| RB
,  ||| S:910 E:912 ||| ,
compared  ||| S:912 E:921 ||| VBN
with  ||| S:921 E:926 ||| IN
fully  ||| S:926 E:932 ||| RB
insured  ||| S:932 E:940 ||| JJ
adolescents ||| S:940 E:951 ||| NNS
,  ||| S:951 E:953 ||| ,
underinsured  ||| S:953 E:966 ||| JJ
adolescents  ||| S:966 E:978 ||| NNS
who  ||| S:978 E:982 ||| WP
received  ||| S:982 E:991 ||| VBD
doses  ||| S:991 E:997 ||| VBN
at  ||| S:997 E:1000 ||| IN
an  ||| S:1000 E:1003 ||| DT
HDC  ||| S:1003 E:1007 ||| NNP
had  ||| S:1007 E:1011 ||| VBD
lower  ||| S:1011 E:1017 ||| RBR
estimated  ||| S:1017 E:1027 ||| JJ
rates  ||| S:1027 E:1033 ||| NNS
of  ||| S:1033 E:1036 ||| IN
vaccination  ||| S:1036 E:1048 ||| JJ
coverage  ||| S:1048 E:1057 ||| NN
for  ||| S:1057 E:1061 ||| IN
tetanus-diphtheria  ||| S:1061 E:1080 ||| FW
toxoids ||| S:1080 E:1087 ||| FW
/ ||| S:1087 E:1088 ||| FW
tetanus  ||| S:1088 E:1096 ||| FW
toxoids-reduced  ||| S:1096 E:1112 ||| FW
diphtheria  ||| S:1112 E:1123 ||| FW
toxoids-acellular  ||| S:1123 E:1141 ||| FW
pertussis  ||| S:1141 E:1151 ||| FW
vaccine  ||| S:1151 E:1159 ||| FW
( ||| S:1159 E:1160 ||| -LRB-
58.5 ||| S:1160 E:1164 ||| NNP
%  ||| S:1164 E:1166 ||| NN
vs  ||| S:1166 E:1169 ||| VBD
70.9 ||| S:1169 E:1173 ||| CD
% ||| S:1173 E:1174 ||| NN
;  ||| S:1174 E:1176 ||| :
P  ||| S:1176 E:1178 ||| NNP
< ||| S:1178 E:1180 ||| SYM
.05 ||| S:1180 E:1183 ||| NNP
) ||| S:1183 E:1184 ||| -RRB-
,  ||| S:1184 E:1186 ||| ,
tetravalent  ||| S:1186 E:1198 ||| FW
meningococcal  ||| S:1198 E:1212 ||| FW
conjugate  ||| S:1212 E:1222 ||| FW
vaccine  ||| S:1222 E:1230 ||| FW
( ||| S:1230 E:1231 ||| -LRB-
10.8 ||| S:1231 E:1235 ||| CD
%  ||| S:1235 E:1237 ||| NN
vs  ||| S:1237 E:1240 ||| VBD
25.8 ||| S:1240 E:1244 ||| CD
% ||| S:1244 E:1245 ||| NN
;  ||| S:1245 E:1247 ||| :
P  ||| S:1247 E:1249 ||| NNP
< ||| S:1249 E:1251 ||| SYM
.05 ||| S:1251 E:1254 ||| NNP
) ||| S:1254 E:1255 ||| -RRB-
,  ||| S:1255 E:1257 ||| ,
and  ||| S:1257 E:1261 ||| CC
quadrivalent  ||| S:1261 E:1274 ||| JJ
human  ||| S:1274 E:1280 ||| JJ
papillomavirus  ||| S:1280 E:1295 ||| JJ
vaccine  ||| S:1295 E:1303 ||| NN
( ||| S:1303 E:1304 ||| -LRB-
7.8 ||| S:1304 E:1307 ||| CD
%  ||| S:1307 E:1309 ||| NN
vs  ||| S:1309 E:1312 ||| VBD
14.3 ||| S:1312 E:1316 ||| CD
% ||| S:1316 E:1317 ||| NN
;  ||| S:1317 E:1319 ||| :
P  ||| S:1319 E:1321 ||| NNP
< ||| S:1321 E:1323 ||| SYM
.05 ||| S:1323 E:1326 ||| NNP
) ||| S:1326 E:1327 ||| -RRB-
.  ||| S:1327 E:1329 ||| .
Underinsured  ||| S:1329 E:1342 ||| JJ
adolescents  ||| S:1342 E:1354 ||| NNS
who  ||| S:1354 E:1358 ||| WP
receive  ||| S:1358 E:1366 ||| VBP
doses  ||| S:1366 E:1372 ||| VBN
at  ||| S:1372 E:1375 ||| IN
an  ||| S:1375 E:1378 ||| DT
HDC  ||| S:1378 E:1382 ||| NNP
have  ||| S:1382 E:1387 ||| VBP
lower  ||| S:1387 E:1393 ||| JJR
rates  ||| S:1393 E:1399 ||| NNS
of  ||| S:1399 E:1402 ||| IN
vaccination  ||| S:1402 E:1414 ||| JJ
coverage  ||| S:1414 E:1423 ||| NN
than  ||| S:1423 E:1428 ||| IN
do  ||| S:1428 E:1431 ||| VBP
fully  ||| S:1431 E:1437 ||| RB
insured  ||| S:1437 E:1445 ||| JJ
adolescents ||| S:1445 E:1456 ||| NNS
.  ||| S:1456 E:1458 ||| .
